uniQure N.V.QUREReports Wed, Nov 4 · Q3 2026
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Netherlands · uniqure.com
uniQure is a gene therapy company developing single treatments with potentially curative results. Its gene therapy for hemophilia B has been approved following more than a decade of research and clinical development. The company is advancing a pipeline of proprietary gene therapies for Huntington's disease, refractory temporal lobe epilepsy, Fabry disease and other severe diseases.
Key ratios
FCF / Sales
-864.7%TTM
2025
-1108.2%2024
-686.2%2023
-966.3%
ROA
-15.7%TTM
2025
-16.2%2024
-16.4%2023
-21.3%
ROE
-157.6%TTM
2025
-207.1%2024
-238.5%2023
-90.2%
Revenue growth
30.2%TTM
2025
-40.6%2024
71.2%2023
-85.1%
Recent news
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for Ifezuntirgene Inilparvovec for the Treatment of Huntington's Disease
uniQure to Announce Third Quarter 2026 Financial Results
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's Disease
Track QURE in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer